Merck & Co's Keytruda produces mixed results in SCLC

Merck & Co’s Keytruda immunotherapy has produced mixed results in a phase 3 trial testing it in first-line extensive-stage small cell lung cancer (SCLC).

Merck & Co joins KRAS gold rush with Taiho and Astex collabo...

US-based Merck & Co has forged an R&D tie-up with Taiho and Astex Pharmaceuticals, focused on developing small molecule drugs targeting the KRAS gene that has become the subject of

AZ, Merck add pancreatic cancer to Lynparza’s growing use li...

FDA clears Eisai’s insomnia drug Dayvigo

2019: the year of the pharma mega-merger

2019 will be remembered as the year of the pharma mega-merger. Richard Staines looks back at a year that changed the landscape of big pharma

Merck claims first-ever FDA approval for an Ebola vaccine